Literature DB >> 7886450

Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis.

A Dessen1, A Quémard, J S Blanchard, W R Jacobs, J C Sacchettini.   

Abstract

Resistance to isoniazid in Mycobacterium tuberculosis can be mediated by substitution of alanine for serine 94 in the InhA protein, the drug's primary target. InhA was shown to catalyze the beta-nicotinamide adenine dinucleotide (NADH)-specific reduction of 2-trans-enoyl-acyl carrier protein, an essential step in fatty acid elongation. Kinetic analyses suggested that isoniazid resistance is due to a decreased affinity of the mutant protein for NADH. The three-dimensional structures of wild-type and mutant InhA, refined to 2.2 and 2.7 angstroms, respectively, revealed that drug resistance is directly related to a perturbation in the hydrogen-bonding network that stabilizes NADH binding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7886450     DOI: 10.1126/science.7886450

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  106 in total

1.  Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil.

Authors:  Rosilene Fressatti Cardoso; Robert C Cooksey; Glenn P Morlock; Patricia Barco; Leticia Cecon; Francisco Forestiero; Clarice Q F Leite; Daisy N Sato; Maria de Lourdes Shikama; Elsa M Mamizuka; Rosario D C Hirata; Mario H Hirata
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis.

Authors:  B Saint-Joanis; H Souchon; M Wilming; K Johnsson; P M Alzari; S T Cole
Journal:  Biochem J       Date:  1999-03-15       Impact factor: 3.857

3.  Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study.

Authors:  André L P da Costa; Ivani Pauli; Márcio Dorn; Evelyn K Schroeder; Chang-Guo Zhan; Osmar Norberto de Souza
Journal:  J Mol Model       Date:  2011-08-12       Impact factor: 1.810

4.  A novel mechanism of growth phase-dependent tolerance to isoniazid in mycobacteria.

Authors:  Makoto Niki; Mamiko Niki; Yoshitaka Tateishi; Yuriko Ozeki; Teruo Kirikae; Astrid Lewin; Yusuke Inoue; Makoto Matsumoto; John L Dahl; Hisashi Ogura; Kazuo Kobayashi; Sohkichi Matsumoto
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

Review 5.  Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

Authors:  A Telenti
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

6.  Molecular basis for triclosan activity involves a flipping loop in the active site.

Authors:  X Qiu; C A Janson; R I Court; M G Smyth; D J Payne; S S Abdel-Meguid
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

Review 7.  Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.

Authors:  Pan Pan; Peter J Tonge
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

Review 8.  The reductase steps of the type II fatty acid synthase as antimicrobial targets.

Authors:  Yong-Mei Zhang; Ying-Jie Lu; Charles O Rock
Journal:  Lipids       Date:  2004-11       Impact factor: 1.880

9.  CHIH-DFT determination of the molecular structure infrared spectra, UV spectra and chemical reactivity of three antitubercular compounds: Rifampicin, Isoniazid and Pyrazinamide.

Authors:  Alejandra Favila; Marco Gallo; Daniel Glossman-Mitnik
Journal:  J Mol Model       Date:  2007-01-27       Impact factor: 1.810

10.  The tuberculosis epidemic. Scientific challenges and opportunities.

Authors:  A M Ginsberg
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.